and /or osteoporosis . 6 The importance of studying the longitudinal and long -term trends in serum prolactin in patients treated with antipsychotics is mandated by these observations.
Based on higher than expected rates of EPS in children and adolescents treated with antipsychotics, Wudarsky and colleagues' hypothesized the possibility of a more robust drug -related prolactin elevation in this age group, possibly reflecting a greater sensitivity of the dopamine systems in young patients. They conducted a 6-week trial in 35 children and adolescents with early -onset psychosis who were treated with 1 of 3 different antipsychotics (ha]operidoi, elozapine, or olanzapine) and found greater prolactin elevation in these pediatric patients than observed in adults, for both the typical antipsychotic h.aloperidol and the atypical. antipsychotic oJ.anzapine.' They noted that these results justified longer observation intervals with bigger samples 'to establish' treatment safety of antipsychotics in this age group. There has also been a report of prolactin elevation in children with autism after 10 weeks of treatment with risperidone.' None of the children showed clinical signs of hyperprolactinemia, but the authors noted the paucity of available data on potential effects of long -term hyperprolactinemia in children during treatment with antipsychotics.
Risperidono is a novel atypical antipsychotic that binds with a high affinity to serotonin 5 -HT, receptors, dopamine D2 receptors, and aradrenergic receptors. Double -blind (DB), pla cebo -controlled trials withrisperidone have demonstràted efficacy in several disorders, including the man.aQement of symptoms associated with conduct and other disruptive behavior disorders in children, adolescents, and adults îti'ith subaverage intellectual functioning or mental retardation in whom destructive behaviors (e.g., aggrressi.on, impulsivity) are prominent. To obtain a substantial amount of data, we decided to pool several studies in children and adolescents 5 to 15 years of age. Two 6 -week DB placebo-controlled trialss°9 with 48 -week open -label (OL) extensions,10'11 phis I additional OL 48 -week trial» included measurements of serum prolactin at several time periods and provided us with the opportunity to evaluate prolactin levels in children and adolescents who received long-term risperidone treatment (up to 55 weeks).
There are no data in children as to the degree of prolactin elevation that warrants concern in relationship to potential inhibition of. growth or sexual development or potential side effects, such as gynecornastia or galactorrh.ea. It is the experience of the authors (pediatric en.docrinologists T.M. and D.D.) that prolactin levels above 18 ng/mL but below 30. ng /mL. are rarely, if ever, associated with clinical manifestations or alterations or the hypothalamic-pituitary-gonadal axis. Prolonged elevations of prolactin approaching serum concentrations of 100 ng /mL warrant careful clinical investigation.
The objective of this post hoc analysis was to investigate serum prolactin levels in children and adolescents who received long-term risperidone treatment and to explore any possible correlation with side effects hypothetically attributable to elevated prolactin levels (SNAP). Because many of these children and adolescents would have been going through puberty, and symptoms associated with hyperprolactinemia, such as gyneconiastia and menstrual disturbances, can also he seen with puberty, possible associations with age and gender were also explored.
METHOD Pooled Study Databases
Five study databases of risperidone -treated children and adolescents were merged. There were two 6 -week, DB placebo -controlled hiais't9 with two 48 -week OL extensions of those trials,10" plus a stand -alone 1 -year OE trial to collect safety data.' One DB trial and OL extension was conducted in the United States (USA), and the other was conducted in Canada, South Africa, and the United States (CAN); the 48 -week DL study was international (trials are summarized below).
USA DB (up to 6 weeks) followed by USA OL extension (up to 48 weeks) CAN DB (up to 6 weeks) followed by CAN OL extension (up to 48 weeks) CAN DB (up to 6 weeks) followed by international OL extension (up to 48 weeks) International OL study (up to 48 weeks)
The protocol specified a 6 -week t,e-aúnent period; however, sufficient blinded medication was provided for extra days beyond the 6 -week trial window to accommodate variability in children's /caregivers' schedules.
Patients were permitted to enter the OL extension provided they had at least 2 weeks of treatm.entduring the DB trial.. The same sponsor designed the studies to be consistent with each other including site training, patient selection criteria, medication dosing, and outcome measures, All studies were conducted in accordance with the Declaration of Helsinki. as revised in 1983 and approved by the institutional review boards at each participating treatment center and by the appropriate regulatory bodies in the respective countries.
Patients
The studies enrolled children and adolescents (outpatients), aged 5 to 14 years inclusive, who bad (1) a DS1v1-I17 Axis I diagnosis of conduct disorder (CD), oppositional defiant disorder, or disruptive behavior disorder not otherwise specified (DBD-NDS); (2) provided that the dose and frequency of use were kept to a minimum. Behavior intervention therapies were allowed provided they had been started at least 30 days prior to trial entry, and every attempt was made to keep the therapy constant throughout the trials.
Outcome Measures
The outcome measures relevant to this analysis included serum prolactin levels, adverse events spontaneously reported by patients /caregivers, and scores on the conduct problem subscale of the N -CBRF.
Prolactin levels were measured at baseline to DB entry and at week 6 or early discontinuation, and then at OL entry, week 4, and at months 3, 6, 9, and 12, Serum prolactin levels were measured by Quest Diagnostics Clinical Trials (Teterboro, NJ.) using an ACS:180 Automated Chemiluminescence System, manufactured by Ciba Coming (Fast Walpole, Mass.) at the time of the studies. Ciba Coming followed National Committee for Clinical Laboratory Standardization. -recommended protocols to determine reference ranges, with calculations based on 95% confidence intervals. The normal ranges used by Quest Diagnostics were used to define the upper limit of normal (LILN) for male and female patients in this analysis. For males, the ULN for serum prolactin was 18 ng/mL, and for females, it was 30 ng /mL. Adverse events were assessed at each study visit, with study visits scheduled at entry and weekly during the DB studies; for OL extension and stand-alone, study visits were weekly for the first month, then at months 3, 6, and 9 and the end of month 11. SHAP were captured from the adverse event database using the broad criteria of those events classified under World Health Organization System Organ Class as "endocrine disorders" or "reproductive disorders" Patients with SNAP were classified according to 2 sets of criteria, SHAP(A) and SHAP(B). The criteria used to define the SHAP(A) population were breast enlargement (gynccomastia), amenorrhea, menorrhagia, lactation nonpuerperal, menstrual disorder, and vaginal hemorrhage. An alternate definition of SNAP was used for the SHAP(B) population. SHAP(B) excluded males 10 years or older with gynecomastia, females with less than 31 days of breast enlargement ( gynecomastia), and females with amenorrhea < 1 week, It is considered normal for males to have gynecomastia at some point in the evolution of puberty, with the frequency estimated as high as 50 %. Adolescent gynecomastia may be unilateral or bilateral, occurs most frequently during stages 3 and 4 of puberty, and lasts a few months to 2 Descriptive statistics were calculated for demographic and predosc patient characteristics, study drug dosing information, and serum prolaetin levels in each analysis time period (prolaetin. levels for all patients, by age, and by gender). Descriptive statistics were also calculated for prolactin levels (by time period) in patients with versus those without SHA., for patients with versus those without EPS at any time, and for responders versus nonresponders on the conduct problem subscale of the N -CERF.
Patient demographics and predose characteristics were compared between the PA and non -PA populations 'using the chi -square test (for categorical data) or t test (for continuous data). As prolactin and EPS are putatively mediated by D2 blockade, and salutary effects might also be moderated by D2 blockade, the chi -square test was also used to compare the percentage of patients who experienced SHAP or EPS or were responders on the conduct problem subscale of the N -CERF among patients with a prolactin level above the ULN versus patients with a prolactin level within the normal range at each study period. Correlation coefficients were calculated to assess the correlation between prolaetin levels and age and score on the conduct problem subscale of the N -CERF. SAS Release 8.00 (SAS Institute Inc., Cary, N.C.) was used for all analyses.
RESULTS
Results are presented for the PA population, who had at least 1 predose and 1 postdose prolactin level observation, unless noted otherwise.
Patient and Treatment Information
When data from all 5 clinical trials were pooled, 700 patients had received at least 1 dose of risperidone and were therefore included in the ITT population_ A total of 592 patients who had a predose and at least 1 postdose prolactin observation at or after 4 18 .0, and 80% of the patients were white.
Prolactin Levels
The mean (SD) predose prolactin. level in the PA population was 7.8 (7.2) ng/mL (Figure 1 ). Prolactin levels tended to rise in the first 4 to 7 weeks of risperidone intake; mean prolactin Level Figure I ). The small group of 42 children and adolescents with prolactin. data at weeks 52 to 55 showed a continued decrease to a mean of 13.0 ng/mL. However, given the small numbers at weeks 52 to 55, no further analyses will be presented in this article.
The incidence of prolactin levels at or above the ULN followed a similar pattern. At baseline, 4.9% of patients had prolactin levels at or above the ULN. This rose to 70.5% at weeks 4 to 7 and then steadily declined to 30.7% at. weeks 40 to 48.
The comparability of prolactin levels was assessed at each time period in patients who discontinued the trial versus those who continued to the next time period. This analysis of fixed subsets did not reveal anynotable differences in the pattern of mean. prolactin levels over time in these 2 groups. The highest mean value occurred during weeks 4 to 7; 29.5 ng/mL in the continuing patient group versus 29.4 ng/mL in the discontinuing patient group.
By gender. The mean predose prolactin level in the males was 7.3 ng/mL, and in the females, it was 10.0 og /mL. Both genders had peak mean prolactin levels in weeks 4 to 7; for males, the mean (SD) was 28.8 (16.0) ng/mL, and for females, the mean was 32.7 (18.3) ng/mL. Prolactin levels steadily decreased to a mean of 15.1 (10.4) ng/mL for males and 21.4 (22.7) ng /mL for females at weeks 40 to 48. The mean value for the females had returned to the normal range (ULN = 30 ng/mL) by weeks 8 to 12 , and the mean for the males was close to normal by weeks 16 to 24 (mean =18.9 ng /mL, ULN = 18 ng/mL).
By age. When prolactin levels were assessed by age group, there was a similar rise and fall in levels over time for each group. There was no correlation between praisetin levels and age at any time period (correlation coefficient values ranged from 0.01 to 0.13).
By gender and age. Females a 9 years of age had mean prolactin levels higher than the ULN at weeks 4 SHAP(A) included gynecomastia irrespective of age, amenorrhea, menorrbagi,a, breast enlargement, lactation nonpuerperal, menstrual disorder, and vaginal hemorrhage. Dysmenorrhea during puberty was excluded.
The SHAP(A) analysis found 34/700 patients (4.9 %) in the ITT population with at least 1 SHAP and 30/592 patients (5.1 %) in the PA population with SHAP ( Table 2) . The most common SHAP was gynecomastia in males: 3.7% of the PA population.
Adverse events corresponding to the analysis definition of SHAP(B) are listed in Prolactin Levels and Score on the Conduct Problem Subscale of the N -CBRF There was no significant correlation between prolactin levels and improvement on the conduct problem subscal.e of the N -OBR (correlation coefficients ranged from 0.10 to 0.02), although behavioral symptom responders tended to have marginally higher mean prolactin levels (maximum 4.1 ng/mL difference) than nonresponders. The lack of significant correlation was consistent whether responders were defined as having improvement of at least 25 %, 35 %, or 50% on the conduct problem subscalc of the N -CBRF.
Prolactin Levels and Risperidone Dose
Correlations between prolactin levels and risperidone dose at each time period were assessed for observed cases on a leg base 10 scale to adjust for skewness. At every time period except weeks 40 to 48, only 0.6% off-re variation in prolactin levels was due to risperidone dose. At weeks 40 to 48, only 1.4% of the variation in prolactin levels could be attributed to risperidone dose.
DISCUSSION
This is the first dataset of children and adolescents treated with an atypical antipsychotic for up to 1 year to clearly demonstrate that although risperidone induced transient elevation in serum prolactin, these levels began to drop after weeks 4 to 7 and returned to within normal limits by weeks 40 to 48 in a majority of patients. It is interesting to note that patients with prolactin levels at or above the 13LN did not have a propensity for greater efficacy response on the conduct problem subseale of the N -CBRF, nor did they have more EPS pr more SHAP than children with normal prolactin levels. The mechanisms underlying this are unclear. It is possible that risperidone's effects on peripheral tuberoinfundibular receptors, although apparently sustained in the first few weeks of exposure, abate due to late dissociation of the It is lmown that prolactin exists not in one but in. many forms. The molecule is subject to dimerization, polymerization, glycosylation, phosphorylation, and diaminaLion.' u Due to size differences, these prolactin variants have been classified as "little," `big," and "big, big" prolactin. Big and big, big prolactin have been reported to have little, if any, biological activity because of decreased binding to prolactin receptors." ``' It has been suggested that lack of hyperprolactinemia-associated symptoms in patients with hyperprolactinemia may be explained by the predominance of the big, big variant.'-s Unfortunately, at the time these trials were conducted, the central laboratory was not asked to specifically assay for the different variants. However, one might speculate that the lack of correlation between SHAD and prolactin may be due in part to a preponderance of the inactive variants of prolactin, as well as the difficulty inherent in defining SHAP within a population in which many of these events may occur as apart of the normal progression through puberty.
The clinical implications of the novel findings of this study are many. First, clinicians can expect that in the vast majority of children and adolescents exposed to long -term therapy with risperidone at these doses, prolactin levels will be raised early in the treatment course, but will revert to levels within normal limits (but in some cases above the baseline prolactin level) without change of dose. There is little justification for the discontinuation or reduction in dose of risperi done or the use of dopamine agonist treatment, since the dose of risperidone did not correlate to prolactin levels. If a highly distressing symptom hypothetically attributable to prolactin (e.g., galactontlea, substantial breast enlargement, especially in males) develops, clinicians must balance the risk-benefit ratio of prescribing risperidone, especially in the face of the effects and outcome of untreated disruptive behavior disorder. Although in some cases prolactin levels did remain above those seen prior to the initiation of risperidone therapy, there is no evidence that untoward effects related to prolactin are likely to be seen at these dosing levels. The low frequency of these side effects in the study populations supports this conclusion.
Drug names. ow+arnazepine (Carhatrol, Tegretol, and others), clonidine (lopidine, Clorpres, and others), clozapine (CIozarii and others), guanfacine (Tenez and others). haloperidol (1laldol and others), methylphenidate (Ritr1ùi, Concerta, and others), afanzapine (Zyprexa), pemoline (Cy ;err and others), risperi done (Risperdal), valproic acid (Depakene and others).
